Search Within

David Hyman

  1. "Alexia Iasonos"
Formats
  1. Journal Article (26)
  2. Meeting Abstract (10)
Groups
  1. Biostatistics Service (36)
  2. Department of Medicine (36)
  3. Early Drug Development Service (36)
  4. Epidemiology and Biostatistics (36)
  5. Solid Tumor Oncology Division (36)
  6. Gynecologic Medicine Service (23)

More Groups

People
  1. Alexia Iasonos (36)
  2. David Spriggs (19)
  3. Rachel Grisham (16)
  4. Carol Aghajanian (15)
  5. Qin Zhou (13)
  6. Mrinal Gounder (9)

More People

Years
  1. 2020 (5)
  2. 2019 (3)
  3. 2018 (1)
  4. 2017 (3)
  5. 2016 (5)
  6. 2015 (6)

More Years

Publications
  1. Journal of Clinical Oncology (13)
  2. Clinical Cancer Research (5)
  3. Cancer (4)
  4. Gynecologic Oncology (3)
  5. International Journal of Gynecological Cancer (3)
  6. Annals of Oncology (1)

More Publications

Publishers
  1. American Society of Clinical Oncology (13)
  2. American Association for Cancer Research (7)
  3. Wiley Blackwell (4)
  4. Elsevier B.V. (3)
  5. Lippincott Williams & Wilkins (3)
  6. Springer (2)

More Publishers

Results (36)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Single-arm, open-label, phase II study of LY3023414 for the treatment of recurrent or persistent endometrial cancer
    Meeting Abstract

    Rubinstein, M. M.; Hyman, D.; Caird, I.; O'Cearbhaill, R.; Grisham, R.; Tew, W.; Hensley, M.; Sabbatini, P.; Aghajanian, C.; Iasonos, A.; more...
    Molecular Cancer Research (2020)

    Fulltext@MSK | Save
  • Landscape and outcome of TRK fusion-positive cancers
    Meeting Abstract

    Rosen, E. Y.; Goldman, D. A.; Hechtman, J. F.; Benayed, R.; Schram, A. M.; Cocco, E.; Shifman, S.; Gong, Y.; Kundra, R.; Solomon, J. P.; more...
    Clinical Cancer Research (2020)

    Fulltext@MSK | Save
  • TRK fusions are enriched in cancers with uncommon histologies and the absence of canonical driver mutations
    Journal Article

    Rosen, E. Y.; Goldman, D. A.; Hechtman, J. F.; Benayed, R.; Schram, A. M.; Cocco, E.; Shifman, S.; Gong, Y.; Kundra, R.; Solomon, J. P.; more...
    Clinical Cancer Research (2020)

    Fulltext@MSK | Save
  • Characteristics and outcome of AKT1(E17K)-mutant breast cancer defined through AACR Project GENIE, a clinicogenomic registry
    Journal Article

    Smyth, L. M.; Zhou, Q.; Nguyen, B.; Yu, C.; Lepisto, E. M.; Arnedos, M.; Hasset, M. J.; Lenoue-Newton, M. L.; Blauvelt, N.; Dogan, S.; more...
    Cancer Discovery (2020)

    Fulltext@MSK | Save
  • Phase 2 study of LY3023414 in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathway
    Journal Article

    Rubinstein, M. M.; Hyman, D. M.; Caird, I.; Won, H.; Soldan, K.; Seier, K.; Iasonos, A.; Tew, W. P.; O’Cearbhaill, R. E.; Grisham, R. N.; more...
    Cancer (2020)

    Fulltext@MSK | Save
  • Use, safety, and efficacy of single-patient use of the US Food and Drug Administration Expanded Access Program
    Journal Article

    Feit, N. Z.; Goldman, D. A.; Smith, E.; Deighan, J.; Iasonos, A.; Zivanovic, O.; Hyman, D. M.
    JAMA Oncology (2019)

    Fulltext@MSK | Save
  • Efficacy of MEK inhibition in patients with histiocytic neoplasms
    Journal Article

    Diamond, E. L.; Durham, B. H.; Ulaner, G. A.; Drill, E.; Buthorn, J.; Ki, M.; Bitner, L.; Cho, H.; Young, R. J.; Francis, J. H.; more...
    Nature (2019)

    Fulltext@MSK | Save
  • Early disease progression and treatment discontinuation in patients with advanced ovarian cancer receiving immune checkpoint blockade
    Journal Article

    Boland, J. L.; Zhou, Q.; Martin, M.; Callahan, M. K.; Konner, J.; O'Cearbhaill, R. E.; Friedman, C. F.; Tew, W.; Makker, V.; Grisham, R. N.; more...
    Gynecologic Oncology (2019)

    Fulltext@MSK | Save
  • A randomized trial of prophylactic extended carboplatin infusion to reduce hypersensitivity reactions in recurrent ovarian cancer
    Journal Article

    LaVigne, K.; Hyman, D. M.; Zhou, Q. C.; Iasonos, A.; Tew, W. P.; Aghajanian, C.; Makker, V.; Hensley, M. L.; Konner, J.; Grisham, R. N.; more...
    International Journal of Gynecological Cancer (2018)

    Fulltext@MSK | Save
  • A phase II trial of enzalutamide in patients with androgen receptor positive (AR+) ovarian, primary peritoneal or fallopian tube cancer and one, two, or three prior therapies
    Meeting Abstract

    Grisham, R. N.; Giri, D. D.; Iasonos, A.; Zhou, Q.; Girshman, J.; McGrath, S. P.; O'Cearbhaill, R. E.; Sabbatini, P.; Tew, W. P.; Hyman, D. M.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save